Posted on August 31st, 2011 by Health News
Results presented today of a Phase III pivotal study for the investigational compound perampanel for partial-onset seizures showed that perampanel, 8 mg and 12 mg, produced statistically significant reductions in median seizure frequency compared to placebo among patients having partial-onset seizures while receiving treatment with one to three other epilepsy drugs.
No Comments »
Filed under: Pharmacy News
Posted on August 31st, 2011 by Health News
Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women’s health and cancer, today announced the positive results from the completion of their tolerability trial of Menerba (MF101) for menopausal hot flashes.
No Comments »
Filed under: Pharmacy News
Posted on August 31st, 2011 by Health News
Adamis Pharmaceuticals Corporation announced today that it enrolled the first patient in its Phase 1/2a clinical prostate study. Adamis’ drug, APC-100, will be used to treat men with castrate-resistant prostate cancer.
No Comments »
Filed under: Pharmacy News
Posted on August 31st, 2011 by Health News
Pearl Therapeutics Inc. today announced positive results from a randomized, double-blind, Phase 2b, dose-ranging study of its formoterol fumarate metered dose inhaler (FF MDI; PT005), a long-acting beta-2 agonist (LABA) compared to placebo and Foradil Aerolizer in patients with moderate-to-severe COPD.
No Comments »
Filed under: Pharmacy News
Posted on August 31st, 2011 by Health News
Aeterna Zentaris Inc. today announced favorable top-line results of its completed Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency.
No Comments »
Filed under: Pharmacy News
Posted on August 31st, 2011 by Health News
Pearl Therapeutics Inc. announced positive results from a randomized, double-blind, Phase 2b, dose-ranging study of its formoterol fumarate metered dose inhaler (FF MDI; PT005), a long-acting beta-2 agonist (LABA) compared to placebo and Foradil® Aerolizer® in patients with moderate-to-severe COPD…
No Comments »
Filed under: Pharmacy News
Posted on August 31st, 2011 by Health News
In order to meet future demands for new pharmaceuticals, innovative materials and agricultural pesticides, the chemical industry is dependent on the ongoing development of effective methods for the synthesis of complex organic compounds. Because they are so versatile, organometallic molecules are of special significance in this context…
No Comments »
Filed under: Pharmacy News
Posted on August 31st, 2011 by Health News
Collaborating researchers at Stanford University and The Scripps Research Institute have identified chemical compounds that show promise as potential therapeutics for a set of medical conditions caused by the abnormal clumping together of a protein known as transthyretin (TTR)…
No Comments »
Filed under: Pharmacy News
Posted on August 31st, 2011 by Health News
Research in Marketing Science by Professor Kamel Jedidi, John A. Howard Professor of Business, Marketing, Columbia Business School; Professor Oded Netzer, Philip H. Geier Jr. Associate Professor, Marketing, Columbia Business School; and Professor Ricardo Montoya, Department of Industrial Engineering, University of Chile, Santiago, Chile, reveals how pharmaceutical managers can maximize the return on marketing investments [...]
No Comments »
Filed under: Pharmacy News
Posted on August 31st, 2011 by Health News
Selecta Biosciences, Inc., a biopharmaceutical company developing an entirely new class of targeted vaccines and immunotherapies, today announced that Science Applications International Corporation (SAIC) has awarded Selecta a subcontract to develop a targeted synthetic vaccine particle product for malaria.
No Comments »
Filed under: Pharmacy News
